of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

Member of the Audit Committee — Mark H. Pavao: Mr. Pavao was appointed to the Audit Committee of the Board.

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

Entry Into a Material Definitive Agreement. On May 12, 2026, Coya Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (“Leerink Partners”), pursuant to which the Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $30,000,000 (the “Placement Shares”). The offer and sal…

Executive Chairman — Dr. Howard Berman: Dr. Howard Berman resigned as Executive Chairman and Director, with a successor appointed.

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On January 29, 2026, Coya Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (collectively, the “ Purchasers ”) for the issuance and sale in a private placement of 2,522,727 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a purchase price of $4.40 per Share (the “ Offering ”). The Offering…

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

of Form 8-K. The Financial Advisor Warrants will be issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D, which is promulgated under the Securities Act. The Company relied on this exemption from registration based in part on representations made by Wilmington.

Entry into a Material Definitive Agreement. On October 23, 2025, Coya Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”) relating to an underwritten public offering (the “Offering”) of 4,181,818 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”), including 545,454 Shares pursuant to the full exercise of an option to purchase additional shares granted to…

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

Director — Dr. Hideki Garren: Dr. Garren resigned due to his new employer's policies.

Chief Executive Officer — Dr. Howard Berman: Dr. Berman resigned as CEO and was succeeded by Dr. Swaminathan.

Unregistered Sales of Equity Securities. The information contained in

Other Items. As of September 30, 2024, the Company had cash and cash equivalents (unaudited) of approximately $31.0 million. This estimate was prepared by the Company based upon internal reporting, is preliminary and unaudited, and may be revised as a result of management’s further review of results as of September 30, 2024. Forward Looking Statements This Current Report on Form 8-K contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Lit…

Entry into a Material Definitive Agreement. On October 21, 2024, Coya Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (collectively, the “ Purchasers ”) for the issuance and sale in a private placement (the “ Private Placement ”) of 1,379,314 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”) at a purchase price of $7.25 per Share (the…

CEO — Dr. Howard Berman: Dr. Howard Berman is resigning as CEO and will be succeeded by Dr. Arun Swaminathan, who is being promoted to CEO.

of this Current Report on Form 8-K as Exhibit 99.1. The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information co…

Entry into a Material Definitive Agreement. On June 4, 2024, Coya Therapeutics, Inc. (the “Company”) entered into the First Amendment to Development and License Agreement (the “First Amendment”) with Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA (collectively, “Dr. Reddy’s”), pursuant to which the parties agreed to amend that certain Development and License Agreement by and between the Company and Dr. Reddy’s, dated December 5, 2023 (the “DRL Development Agreeme…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 17, 2024, Coya Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Alzheimer’s Drug Discovery Foundation (the “ADDF”) for the issuance and sale in a private placement (the “Private Placement”) of 603,136 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $8.29 per share for gross…